Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17636656 | 0.96 | MAPT (0.42) | MAPTMDM2KMT2A | |
| SCHEMBL17636653 | 0.96 | MAPT (0.42) | MAPTMDM2POLBSMN1; SMN2RXFP1 | |
| SCHEMBL17636680 | 0.94 | MAPT (0.40) | MAPTPOLBSMN1; SMN2RXFP1CHRNB2 | |
| SCHEMBL17636650 | 0.91 | MAPT (0.43) | MAPTPOLBSMN1; SMN2RXFP1 | |
| SCHEMBL17636669 | 0.90 | MAPT (0.42) | MAPTGRM1CYP1A2METAP2 | |
| SCHEMBL18538760 | 0.88 | MDM2 (0.44) | MDM2KMT2ACYP1A2METAP2 | |
| SCHEMBL17636641 | 0.87 | MAPT (0.41) | MAPTPOLBSMN1; SMN2RXFP1CHRNB2 | |
| SCHEMBL17636678 | 0.86 | MAPT (0.43) | MAPTPOLBSMN1; SMN2RXFP1 | |
| SCHEMBL17636693 | 0.86 | MAPT (0.39) | MAPTPOLBSMN1; SMN2RXFP1CHRNB2 | |
| SCHEMBL17636642 | 0.86 | KDM4E (0.41) | SMN1; SMN2KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9960365-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-9960365-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-20160093811-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-03-31 | — | — | US | disclosed |
| US-20160093811-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160093811-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, CCNA1 | MAPT 1845/4885MDM2 3191/4885POLB 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.